Use of ivermectin in the treatment of COVID-19: a review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | MedNEXT Journal of Medical and Health Sciences |
Texto Completo: | https://mednext.zotarellifilhoscientificworks.com/index.php/mednext/article/view/130 |
Resumo: | Introduction: SARS-CoV-2 produces a respiratory syndrome that can range from a mild, self-limiting inflammatory condition to severe, progressive pneumonia. Prevention and treatment strategies have become a priority since the emergence of COVID-19. Noteworthy is the use of ivermectin, an anti-parasitic agent, which has been widely recommended by some health professionals for the prevention and treatment of COVID-19. Objective: To assess the evidence on the efficacy and safety of using ivermectin for the prevention and treatment of COVID-19, identifying its mode of action and the benefits and adverse reactions of using this drug. Methods: The search strategy for articles was based on a search in the electronic databases MEDLINE (NationalLibrary of Medicine, United States), LILACS (Latin American and Caribbean Literature in Health Sciences), Scielo, specialized libraries of Universities, PubMed, and Google Academic. The selected articles will be from 2015 to 2021. Results and Conclusion: Studies reveal that ivermectin is a broad-spectrum drug with high-fat solubility and has numerous effects on several parasites. In addition to having antiviral and antiparasitic effects, this drug also causes immunomodulation in the host. Ivermectin has already demonstrated its potent antiviral effects in vitro against several RNA viruses, such as influenza A, Zika virus, Newcastle disease virus, yellow fever virus, Chikungunya virus, dengue virus, among others. One way to delay viral transmission would be to stop the virus from replicating, thus reducing the viral load in infected individuals. Thus, studies have shown that ivermectin may have the potential for inhibiting and replicating SARS-CoV-2. |
id |
FACERES-1_b72925c7fced7ce9128d871dba01ae0f |
---|---|
oai_identifier_str |
oai:ojs2.mednext.zotarellifilhoscientificworks.com:article/130 |
network_acronym_str |
FACERES-1 |
network_name_str |
MedNEXT Journal of Medical and Health Sciences |
repository_id_str |
|
spelling |
Use of ivermectin in the treatment of COVID-19: a reviewCOVID-19SARS-CoV-2IvermectinTreatmentPreventionIntroduction: SARS-CoV-2 produces a respiratory syndrome that can range from a mild, self-limiting inflammatory condition to severe, progressive pneumonia. Prevention and treatment strategies have become a priority since the emergence of COVID-19. Noteworthy is the use of ivermectin, an anti-parasitic agent, which has been widely recommended by some health professionals for the prevention and treatment of COVID-19. Objective: To assess the evidence on the efficacy and safety of using ivermectin for the prevention and treatment of COVID-19, identifying its mode of action and the benefits and adverse reactions of using this drug. Methods: The search strategy for articles was based on a search in the electronic databases MEDLINE (NationalLibrary of Medicine, United States), LILACS (Latin American and Caribbean Literature in Health Sciences), Scielo, specialized libraries of Universities, PubMed, and Google Academic. The selected articles will be from 2015 to 2021. Results and Conclusion: Studies reveal that ivermectin is a broad-spectrum drug with high-fat solubility and has numerous effects on several parasites. In addition to having antiviral and antiparasitic effects, this drug also causes immunomodulation in the host. Ivermectin has already demonstrated its potent antiviral effects in vitro against several RNA viruses, such as influenza A, Zika virus, Newcastle disease virus, yellow fever virus, Chikungunya virus, dengue virus, among others. One way to delay viral transmission would be to stop the virus from replicating, thus reducing the viral load in infected individuals. Thus, studies have shown that ivermectin may have the potential for inhibiting and replicating SARS-CoV-2.Faceres2022-02-22info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/otherapplication/pdfhttps://mednext.zotarellifilhoscientificworks.com/index.php/mednext/article/view/13010.54448/mdnt22107MedNEXT Journal of Medical and Health Sciences; Vol. 3 No. 1 (2022): MedNEXTMedNEXT Journal of Medical and Health Sciences; v. 3 n. 1 (2022): MedNEXT2763-567810.54448/mdnt221reponame:MedNEXT Journal of Medical and Health Sciencesinstname:Faculdade de Medicina em São José do Rio Preto (Faceres)instacron:FACERESenghttps://mednext.zotarellifilhoscientificworks.com/index.php/mednext/article/view/130/128Copyright (c) 2022 MedNEXT Journal of Medical and Health Scienceshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessZanoti, Eduardo BertolliniPorto, Rodrigo MagalhãesScriboni, Andreia Borges2022-02-22T20:29:09Zoai:ojs2.mednext.zotarellifilhoscientificworks.com:article/130Revistahttps://mednext.zotarellifilhoscientificworks.com/index.php/mednextPUBhttps://mednext.zotarellifilhoscientificworks.com/index.php/mednext/oaimednextjmhs@zotarellifilhoscientificworks.com2763-56782763-5678opendoar:2022-02-22T20:29:09MedNEXT Journal of Medical and Health Sciences - Faculdade de Medicina em São José do Rio Preto (Faceres)false |
dc.title.none.fl_str_mv |
Use of ivermectin in the treatment of COVID-19: a review |
title |
Use of ivermectin in the treatment of COVID-19: a review |
spellingShingle |
Use of ivermectin in the treatment of COVID-19: a review Zanoti, Eduardo Bertollini COVID-19 SARS-CoV-2 Ivermectin Treatment Prevention |
title_short |
Use of ivermectin in the treatment of COVID-19: a review |
title_full |
Use of ivermectin in the treatment of COVID-19: a review |
title_fullStr |
Use of ivermectin in the treatment of COVID-19: a review |
title_full_unstemmed |
Use of ivermectin in the treatment of COVID-19: a review |
title_sort |
Use of ivermectin in the treatment of COVID-19: a review |
author |
Zanoti, Eduardo Bertollini |
author_facet |
Zanoti, Eduardo Bertollini Porto, Rodrigo Magalhães Scriboni, Andreia Borges |
author_role |
author |
author2 |
Porto, Rodrigo Magalhães Scriboni, Andreia Borges |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Zanoti, Eduardo Bertollini Porto, Rodrigo Magalhães Scriboni, Andreia Borges |
dc.subject.por.fl_str_mv |
COVID-19 SARS-CoV-2 Ivermectin Treatment Prevention |
topic |
COVID-19 SARS-CoV-2 Ivermectin Treatment Prevention |
description |
Introduction: SARS-CoV-2 produces a respiratory syndrome that can range from a mild, self-limiting inflammatory condition to severe, progressive pneumonia. Prevention and treatment strategies have become a priority since the emergence of COVID-19. Noteworthy is the use of ivermectin, an anti-parasitic agent, which has been widely recommended by some health professionals for the prevention and treatment of COVID-19. Objective: To assess the evidence on the efficacy and safety of using ivermectin for the prevention and treatment of COVID-19, identifying its mode of action and the benefits and adverse reactions of using this drug. Methods: The search strategy for articles was based on a search in the electronic databases MEDLINE (NationalLibrary of Medicine, United States), LILACS (Latin American and Caribbean Literature in Health Sciences), Scielo, specialized libraries of Universities, PubMed, and Google Academic. The selected articles will be from 2015 to 2021. Results and Conclusion: Studies reveal that ivermectin is a broad-spectrum drug with high-fat solubility and has numerous effects on several parasites. In addition to having antiviral and antiparasitic effects, this drug also causes immunomodulation in the host. Ivermectin has already demonstrated its potent antiviral effects in vitro against several RNA viruses, such as influenza A, Zika virus, Newcastle disease virus, yellow fever virus, Chikungunya virus, dengue virus, among others. One way to delay viral transmission would be to stop the virus from replicating, thus reducing the viral load in infected individuals. Thus, studies have shown that ivermectin may have the potential for inhibiting and replicating SARS-CoV-2. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-02-22 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/other |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://mednext.zotarellifilhoscientificworks.com/index.php/mednext/article/view/130 10.54448/mdnt22107 |
url |
https://mednext.zotarellifilhoscientificworks.com/index.php/mednext/article/view/130 |
identifier_str_mv |
10.54448/mdnt22107 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://mednext.zotarellifilhoscientificworks.com/index.php/mednext/article/view/130/128 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2022 MedNEXT Journal of Medical and Health Sciences https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2022 MedNEXT Journal of Medical and Health Sciences https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Faceres |
publisher.none.fl_str_mv |
Faceres |
dc.source.none.fl_str_mv |
MedNEXT Journal of Medical and Health Sciences; Vol. 3 No. 1 (2022): MedNEXT MedNEXT Journal of Medical and Health Sciences; v. 3 n. 1 (2022): MedNEXT 2763-5678 10.54448/mdnt221 reponame:MedNEXT Journal of Medical and Health Sciences instname:Faculdade de Medicina em São José do Rio Preto (Faceres) instacron:FACERES |
instname_str |
Faculdade de Medicina em São José do Rio Preto (Faceres) |
instacron_str |
FACERES |
institution |
FACERES |
reponame_str |
MedNEXT Journal of Medical and Health Sciences |
collection |
MedNEXT Journal of Medical and Health Sciences |
repository.name.fl_str_mv |
MedNEXT Journal of Medical and Health Sciences - Faculdade de Medicina em São José do Rio Preto (Faceres) |
repository.mail.fl_str_mv |
mednextjmhs@zotarellifilhoscientificworks.com |
_version_ |
1796798219917721600 |